Manufacturers announces positive data for mavrilimumab in severe COVID-19 pneumonia and hyperinflammation

Interim data from an adaptive phase 2/3 RCT (n=40) found a 20% increase in the proportion of patients alive and off supplemental oxygen at Day 14 vs placebo (57.1% vs 47.4%) though this was not statistically significant. Mavrilimumab is a monoclonal antibody targeting GM-CSFRα.

Biospace Inc.